Mergers and Acquisitions

Latest Headlines

Latest Headlines

Bayer makes prelim offer for Pfizer's animal health unit

Bayer CEO Marijn Dekkers thinks Pfizer ($PFE) is most likely to spin off its animal health unit. But the German company made a preliminary offer anyway, Dow Jones reports, citing the Financial Times Deutschland.

Stada stymied in bids for Russian M&A

Germany's Stada wants to expand in Russia. But attempts to buy Russian drugmakers have so far failed--despite months of effort--leaving the company with a big debt burden and stagnant home market, Reuters reports.

Divestments 'not a trivial exercise,' Read tells FT

Pfizer ($PFE) CEO Ian Read (photo) told the Financial Times that he hopes to divest the company's animal health and nutrition units by June 13.

Shire nabs Bay Area's FerroKin, orphan drug in $325M buyout

Fresh off a disappointing decision to jerk its marketing application for Replagal, Shire bounced right back with its announcement that it has scooped up the Bay Area biotech FerroKin BioSciences in a $325 million deal. Shire is paying $100 million upfront for FerroKin, with the rest offered in potential milestones.

Okairos launches pioneering mid-stage study of promising hep C vaccine

As far as most biotech investors are concerned, the most exciting work being done in the hepatitis C field involves next-gen treatments that can potentially quell the virus without the need for the troublesome interferon in the combo.

With Seroquel petition denied, AZ needs M&A

The FDA has officially denied AstraZeneca's petition to hold off generic versions of its antipsychotic drug Seroquel.

Generics deals drive increase in pharma M&A

Pharma M&A activity is heating up, particularly among medium-sized companies, and shows signs of accelerating further, MarketWatch reports.

Viehbacher up on Boston, emerging markets, down on corporate innovation

Sanofi ($SNY) CEO Chris Viehbacher (photo) managed to parlay one personal appearance into a half-dozen different headlines. Development strategies? Check. M&A interest? Check. Job creation?...

Abcam's $155M Epitomics buyout expands antibody business

Bidding to up its game in the antibody business, the U.K.'s Abcam has snapped up California-based Epitomics for $155 million.

GSK to add hundreds to Chinese sales force, CEO says

GlaxoSmithKline ($GSK) is steaming ahead in China. CEO Andrew Witty (photo) tells Bloomberg he plans to add "a few hundred" sales folks to back up products his company is introducing there. That's on top of 700 hires in 2011. And, Witty said, he'd like to augment his Chinese operations with some M&A, too.